Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jose Maria M. Piulats Rodriguez"'
Autor:
Ulka N. Vaishampayan, Haiyan Wu, Emmanuel S. Antonarakis, Johann S. de Bono, Ken-ichi Tabata, Jeri Kim, Jeffrey C. Goh, Charles Schloss, Ronald de Wit, Satoshi Fukasawa, Jose Maria M. Piulats Rodriguez, Marine Gross-Goupil, Susan Feyerabend, Raanan Berger, Tuomo Alanko
Publikováno v:
Journal of Clinical Oncology. 38:e17584-e17584
e17584 Background: Pembrolizumab monotherapy has shown antitumor activity and acceptable safety in patients with mCRPC previously treated with a next-generation hormone agent (NHA) and docetaxel. Presented herein are updated results from KEYNOTE-199
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed728f84bb7988e24146d7825cd2e020
https://doi.org/10.1200/jco.2020.38.15_suppl.e17584
https://doi.org/10.1200/jco.2020.38.15_suppl.e17584
Autor:
Ronald de Wit, Jeffrey C. Goh, Charles Schloss, Jose Maria M. Piulats Rodriguez, Haiyan Wu, Emmanuel S. Antonarakis, Tuomo Alanko, Marine Gross-Goupil, Ulka N. Vaishampayan, Johann S. de Bono, Razvan Cristescu, Ken-ichi Tabata, Ping Qiu, Leah Suttner, Satoshi Fukasawa, Jeri Kim, Matthew J. Marton, Susan Feyerabend, Raanan Berger
Publikováno v:
Journal of Clinical Oncology. 38:5526-5526
5526 Background: In the phase II KEYNOTE-199 study (NCT02787005), pembrolizumab monotherapy demonstrated antitumor activity in pts with docetaxel-refractory mCRPC (n = 258). Here we evaluated the association between prespecified molecular biomarkers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2ba42ace97228b41258303375d1ccf2
https://doi.org/10.1200/jco.2020.38.15_suppl.5526
https://doi.org/10.1200/jco.2020.38.15_suppl.5526
Autor:
Amaia Hernandez, Elena Castro, Elena Almagro, Nuria Romero-Laorden, R. Villatoro, Casilda Llacer Perez, Carlo Cattrini, David Lorente, Jose Maria M. Piulats Rodriguez, Enrique Gallardo Diaz, Pablo Borrega, Nuria Lainez, Rebeca Lozano, Pedro P. López-Casas, Francesca Vitrone, Ana Medina, David Olmos, Javier Puente, Alejo Rodriguez-Vida, L. Rivera
Publikováno v:
Journal of Clinical Oncology. 38:5554-5554
5554 Background: The CARD trial proved that in mCPRC patients (pts), previously treated with docetaxel and an androgen-receptor signaling inhibitor (ARSi), cabazitaxel (CBZ) significantly improves progression-free (PFS) and Overall Survival (OS) comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77f4b7e83a867b3394f41fadb44f6190
https://doi.org/10.1200/jco.2020.38.15_suppl.5554
https://doi.org/10.1200/jco.2020.38.15_suppl.5554
Autor:
Leonard Joseph Appleman, Howard Gurney, Haiyan Wu, Ping Qiu, Emanuela Romano, Urban Emmenegger, Brigitte Laguerre, Loic Mourey, Margitta Retz, Henry Jacob Conter, Johann S. de Bono, Gwenaelle Gravis, Martin Boegemann, Charles Schloss, Michael Paul Kolinsky, Jose Maria M. Piulats Rodriguez, Srikala S. Sridhar, William R. Berry, Anthony M. Joshua, Evan Y. Yu
Publikováno v:
Web of Science
5550 Background: Pembro + docetaxel and prednisone (cohort B) has shown antitumor activity in pts with mCRPC in the phase I/II KEYNOTE-365 study (NCT02861573). Updated efficacy and safety and new biomarker data from cohort B are reported. Methods: Pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de62d1bdf9f3ced71cf566adcd2e4e78
https://doi.org/10.1200/jco.2020.38.15_suppl.5550
https://doi.org/10.1200/jco.2020.38.15_suppl.5550
Autor:
Elena Castro, Jose Maria M. Piulats Rodriguez, Enrique Gonzalez-Billalabeitia, David Lorente, Pablo Borrega, Rebeca Lozano, Alejo Rodriguez Vida, Aranzazu Gonzalez del Alba, Rafael Morales Barrera, Angela del Pozo, Iciar Garcia Carbonero, Pablo Lapunzina, Javier Puente, M Isabel Sáez, Eva Fernandez Parra, Nuria Romero-Laorden, María José Méndez-Vidal, Ana Medina, David Olmos, Colin C. Pritchard
Publikováno v:
Journal of Clinical Oncology. 36:5071-5071
5071Background: Germline mutations in BRCA2 have been identified in 3-5% of mCRPC patients. PROREPAIR-B (Castro et al ESMO 2017) is the first prospective study to report a worse survival from mCRPC...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b48d06df186b2d54c36dcc120b14a15
https://doi.org/10.1200/jco.2018.36.15_suppl.5071
https://doi.org/10.1200/jco.2018.36.15_suppl.5071
Autor:
Kristiina Ojamaa, Haiyan Wu, Christian Heinrich Poehlein, Christopher J. Hoimes, Jose Maria M. Piulats Rodriguez, Emmanuel S. Antonarakis, Charles G. Drake, Jeffrey C. Goh, Johann S. de Bono
Publikováno v:
Journal of Clinical Oncology. 36:5007-5007
5007Background: Efficacy of PD-1 inhibition has not been demonstrated in large-scale mCRPC trials. Pembro showed preliminary antitumor activity in PD-L1+ mCRPC in KEYNOTE-028 (n = 23). Here, we present results from cohorts 1-3 (n = 258) of the phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2059f29042d5a9d4aa00c7f6807a9c61
https://doi.org/10.1200/jco.2018.36.15_suppl.5007
https://doi.org/10.1200/jco.2018.36.15_suppl.5007
Autor:
Christopher J. Logothetis, Charles J. Ryan, Robert Jones, Deborah Ricci, Jose Maria M. Piulats Rodriguez, Henitz Erin Devay, John J. Gullo, Henrik Suttmann, Alfons J.M. van den Eertwegh, Gerhardt Attard, Weimin Li, Joan Carles, Eleni Efstathiou, Johann S. de Bono, Dirk Schrijvers, Howard I. Scher, Michael Gormley, Thomas W. Griffin, Dana E. Rathkopf
Publikováno v:
Journal of Clinical Oncology. 32:5058-5058
5058 Background: AA is metabolized to abiraterone, a CYP17 inhibitor that blocks testicular, adrenal, and tumoral androgen biosynthesis. AA is approved for the treatment of metastatic castration-re...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61e43ffe937e20fb58b1d574b15c0398
https://doi.org/10.1200/jco.2014.32.15_suppl.5058
https://doi.org/10.1200/jco.2014.32.15_suppl.5058
Autor:
Maria Ochoa de Olza, Jose Maria M. Piulats Rodriguez, Margarita García, Manuel Codes, Blanca Homet, Jose A. Lopez-Martin, Alfonso Berrocal, Alfonso Gurpide, Salvador Martín-Algarra
Publikováno v:
Journal of Clinical Oncology. 32:9033-9033
9033 Background: Uveal melanoma is the most common primary intraocular malignant tumor in adults. Overall survival (OS) at 5 years is 62% due to high incidence of liver metastasis that are fatal wi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15e99282e3ca6a55dc04941485917bf4
https://doi.org/10.1200/jco.2014.32.15_suppl.9033
https://doi.org/10.1200/jco.2014.32.15_suppl.9033
Autor:
Matthew R. Smith, Jose Maria M. Piulats Rodriguez, Peter F.A. Mulders, Arturo Molina, Paul N. Mainwaring, Karim Fizazi, Dana E. Rathkopf, Thomas W. Griffin, Joan Carles, Thian Kheoh, Howard I. Scher, Eric J. Small, Johann S. de Bono, Christopher J. Logothetis, Paul de Souza, Charles J. Ryan, Siobhan Ng
Publikováno v:
Journal of Clinical Oncology. 30:LBA4518-LBA4518
LBA4518 Background: AA is an androgen biosynthesis inhibitor that inhibits CYP17 and improves overall survival (OS) in post-docetaxel mCRPC. The primary objective of COU-AA-302 was to compare clinical benefit of AA + prednisone (P) vs placebo (PL) +
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::240806cce4e9b38f82d3bcd77639344c
https://doi.org/10.1200/jco.2012.30.15_suppl.lba4518
https://doi.org/10.1200/jco.2012.30.15_suppl.lba4518
Autor:
Charles Schloss, Evan Y. Yu, Peter C.C. Fong, Leonard Joseph Appleman, Brigitte Laguerre, Howard Gurney, Loic Mourey, Jose Maria M. Piulats Rodriguez, William R. Berry, Margitta Retz, Tilman Todenhöfer, Haiyan Wu, Urban Emmenegger, Emanuela Romano, Neal D. Shore, Ping Qiu, Gwenaelle Gravis, Audrey E. Kam, Henry Jacob Conter, Johann S. de Bono
Publikováno v:
Web of Science
5545 Background: Pembro + enza (cohort C) has shown antitumor activity and acceptable safety in abi-pretreated pts with mCRPC in the phase I/II KEYNOTE-365 study (NCT02861573). Updated results with new biomarker data from cohort C are reported. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f73d74760ae5a52be237ae7f758785f5
https://publons.com/publon/35436183/
https://publons.com/publon/35436183/
